Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis (BACTOvation™)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01877694
Recruitment Status : Completed
First Posted : June 14, 2013
Last Update Posted : May 28, 2015
Information provided by (Responsible Party):
NovaBay Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.

Condition or disease Intervention/treatment Phase
Bacterial Conjunctivitis Drug: Auriclosene Solution 0.3% Drug: Auriclosene Vehicle Phase 2

Detailed Description:

This is a randomized (1:1) double-masked, vehicle-controlled, multi-center, parallel group study with two treatment arms: Auriclosene Ophthalmic Solution 0.3% ("Auriclosene") and Auriclosene Vehicle ("Vehicle").

Subjects that meet all inclusion/exclusion criteria will be enrolled into the study, randomized and evaluated at 3 visits:

  • Visit 1: Screening, Day 1
  • Visit 2: Day 3 (±1)
  • Visit 3: Day 5 (+1) Test of Cure/Exit

IP will be dosed OU (both eyes) QID for 4 days. Microbiological specimens will be collected from each eye at each visit.

Visual Acuity will be assessed OU at each visit as well as rating of the ocular signs: lid erythema and swelling, bulbar and palpebralconjunctival injection, and conjunctival discharge/exudate.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 217 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Study Start Date : June 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pinkeye

Arm Intervention/treatment
Experimental: Auriclosene Solution 0.3%
Dosed QID for 4 Days
Drug: Auriclosene Solution 0.3%
Ophthalmic solution dispensed as drops onto the eye
Other Name: NVC-422

Placebo Comparator: Auriclosene Vehicle
Dosed QID for 4 days
Drug: Auriclosene Vehicle
Ophthalmic Vehicle solution dispensed as drops onto the eye

Primary Outcome Measures :
  1. Microbiological Success [ Time Frame: 5 days ]
    Eradication of all pre-therapy isolates

Secondary Outcome Measures :
  1. Clinical Cure [ Time Frame: 5 days ]
    Resolution of all signs and symptoms

Other Outcome Measures:
  1. Resolution of individual ocular signs and symptoms [ Time Frame: 5 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1 year of age and older
  • Bulbar conjunctival injection
  • Conjunctival discharge/exudate
  • Signs and symptoms of bacterial conjunctivitis in at least one eye for 3 days or less
  • Other inclusion criteria per protocol

Exclusion Criteria:

  • Suspected fungal, viral, Chlamydia or Acanthamoeba co-infection based on clinical diagnosis
  • Any drug treatment in either eye for the current episode of bacterial conjunctivitis prior to study enrollment
  • Other exclusion criteria per protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01877694

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35244
United States, Arizona
Phoenix, Arizona, United States, 85032
United States, California
Anaheim, California, United States, 92804
Bellflower, California, United States, 90706
Glendale, California, United States, 91204
Huntington Beach, California, United States, 92647
United States, Florida
Clearwater, Florida, United States, 33761
United States, Georgia
Woodstock, Georgia, United States, 30189
United States, Indiana
Evansville, Indiana, United States, 47714
United States, Kansas
Newton, Kansas, United States, 67114
United States, New Jersey
Whitehouse Station, New Jersey, United States, 08889
United States, North Carolina
Huntersville, North Carolina, United States, 28078
Winston Salem, North Carolina, United States, 27101
United States, Ohio
Cincinnati, Ohio, United States, 45246
Dayton, Ohio, United States, 45432
United States, Texas
Corsicana, Texas, United States, 75110
San Antonio, Texas, United States, 78215
United States, Utah
Clinton, Utah, United States, 84015
United States, Virginia
Charlottesville, Virginia, United States, 22902
Midlothian, Virginia, United States, 23113
United States, Washington
Spokane, Washington, United States, 99202
Sponsors and Collaborators
NovaBay Pharmaceuticals, Inc.
Layout table for investigator information
Study Director: David W. Stroman, Ph.D. NovaBay Pharmaceuticals, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: NovaBay Pharmaceuticals, Inc. Identifier: NCT01877694    
Other Study ID Numbers: CL1301
First Posted: June 14, 2013    Key Record Dates
Last Update Posted: May 28, 2015
Last Verified: May 2015
Keywords provided by NovaBay Pharmaceuticals, Inc.:
pink eye
Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctivitis, Bacterial
Conjunctival Diseases
Eye Diseases
Eye Infections, Bacterial
Bacterial Infections
Eye Infections
Ophthalmic Solutions
Pharmaceutical Solutions